McDonald M B, Deitz M R, Frantz J M, Kraff M C, Krueger R R, Salz J J, Kraff C R, Maguen E, Matta C S, Nesburn A B, Piebenga L W
Refractive Surgery Center of the South, Eye, Ear, Nose and Throat Hospital, New Orleans, Louisiana, USA.
Ophthalmology. 1999 Aug;106(8):1481-8; discussion 1488-9. doi: 10.1016/S0161-6420(99)90440-2.
To assess the safety and effectiveness of the Autonomous Technologies Corporation LADARVision excimer laser system for photorefractive keratectomy correction of myopia and astigmatism.
A multicenter, prospective, noncomparative case series.
The cohort consisted of 467 eyes corrected for spherical myopia and 211 eyes corrected for myopia with astigmatism.
Treatments were performed at six sites in the United States using a 6-mm ablation zone for spherical myopes and a 5.5-mm zone with a 1.0-mm blend for astigmats.
Visual acuity, subjective refraction, corneal haze, intraocular pressure, complications, adverse reactions, patient satisfaction, and corneal endothelial changes.
Twelve-month follow-up was available on 414 spherical eyes and 175 astigmatic eyes. The results for spherical eyes with correction between -1 and -5.99 diopters (D) were: uncorrected visual acuity (UCVA) of 20/40 or better achieved by 98.1%, 20/20 or better by 72%, 1.8% lost 2 lines and 0.3% lost greater than 2 lines of best spectacle-corrected visual acuity (BSCVA); 76.4% were within 0.50 D of the target correction and 94.4% were within 1.00 D. The results for myopia with astigmatism with spherical equivalent correction between -1 and -5.99 D were: UCVA of 20/40 or better in 97.4%, 20/20 or better in 61.7%, 2.5% lost 2 lines and no eyes lost greater than 2 lines BSCVA; 73.9% were within 0.50 D of the target correction and 95% were within 1.00 D. For spherical myopes combined with myopic astigmats corrected for 6 to 10 D, results were: UCVA of 20/40 or better in 93.4%, 20/20 or better in 61.2%, 2.3% lost 2 lines and no eyes lost greater than 2 lines of BSCVA; 67.2% were within 0.50 D of the desired correction and 87.8% were within 1.00 D. Refractive stability was achieved between 3 and 6 months for the spherical and astigmatic groups. No eyes had corneal haze graded as moderate or greater, and there was no significant decrease in endothelial cell density.
Patients treated for 1 to 10 D of spherical equivalent myopia, with or without astigmatism, showed early refractive stability, excellent UCVA, no significant loss of BSCVA, no loss of endothelial cell density, and very low levels of corneal haze to 12 months after surgery.
评估自主技术公司的LADARVision准分子激光系统用于近视和散光的光性屈光性角膜切削术矫正的安全性和有效性。
一项多中心、前瞻性、非对照病例系列研究。
该队列包括467只矫正单纯性近视的眼睛和211只矫正近视合并散光的眼睛。
在美国的六个地点进行治疗,单纯性近视患者采用6毫米的消融区,近视合并散光患者采用5.5毫米的区域并带有1.0毫米的融合区。
视力、主观验光、角膜混浊、眼压、并发症、不良反应、患者满意度以及角膜内皮变化。
对414只单纯性近视眼睛和175只散光眼睛进行了12个月的随访。矫正度数在-1至-5.99屈光度(D)之间的单纯性近视眼睛的结果为:98.1%的患者未矫正视力(UCVA)达到20/40或更好,72%的患者达到20/20或更好,1.8%的患者视力下降2行,0.3%的患者视力下降超过最佳矫正视力(BSCVA)2行;76.4%的患者在目标矫正度数的0.50 D范围内,94.4%的患者在1.00 D范围内。矫正度数在-1至-5.99 D之间的近视合并散光眼睛的结果为:97.4%的患者UCVA达到20/40或更好,61.7%的患者达到20/20或更好,2.5%的患者视力下降2行,没有眼睛视力下降超过BSCVA 2行;73.9%的患者在目标矫正度数的0.50 D范围内,95%的患者在1.00 D范围内。对于矫正度数为6至10 D的单纯性近视合并近视性散光患者,结果为:93.4%的患者UCVA达到20/40或更好,61.2%的患者达到20/20或更好,2.3%的患者视力下降2行,没有眼睛视力下降超过BSCVA 2行;67.2%的患者在预期矫正度数的0.50 D范围内,87.8%的患者在1.00 D范围内。单纯性近视组和散光组在3至6个月时屈光状态达到稳定。没有眼睛的角膜混浊分级为中度或更严重,内皮细胞密度也没有显著下降。
接受1至10 D等效球镜度近视治疗的患者,无论有无散光,术后12个月均显示出早期屈光稳定性、优异的UCVA、BSCVA无显著下降、内皮细胞密度无损失以及角膜混浊程度极低。